Science & TechnologySource: The Hindu
Innovative Treatment Approaches for Drug-Resistant Pneumonia using Nitric Oxide
Monday, 16 February 2026
Read Original ArticleKey Points
Innovative Treatment Approaches for drug-resistant pneumonia have emerged, particularly using high-dose inhaled nitric oxide (300 ppm). This treatment significantly reduces the incidence of drug-resistant pneumonia, especially caused by Pseudomonas aeruginosa, a major concern in ICUs. The study underscores the importance of finding new strategies to tackle antimicrobial resistance.
Detailed Coverage
- High-dose inhaled nitric oxide (300 ppm) shows promise against drug-resistant pneumonia.
- Drug-resistant pneumonia is a severe issue in Intensive Care Units (ICUs).
- Responsible for approximately one in five hospital pneumonias.
- Condition caused by bacteria resistant to antibiotics.
- Key pathogens include Streptococcus pneumoniae and MRSA.
- Gram-negative bacteria like Pseudomonas aeruginosa are prevalent in hospital-acquired pneumonia.
- Delayed response can lead to severe outcomes, including sepsis or death.
- Nitric oxide is a colorless gas with a short half-life.
- Produced from L-arginine by nitric oxide synthases (NOS).
- Functions as a vasodilator in the cardiovascular system.
- Acts as a neurotransmitter in the nervous system.
- Exhibits antimicrobial properties, disrupting pathogen metabolism.
- Discovery of nitric oxide led to the 1998 Nobel Prize in Physiology.
- The study emphasizes innovative approaches to combat antimicrobial resistance.
- Highlights the need for new treatment strategies.
- Potential game-changer in managing drug-resistant infections.
Science & Technology